Christopher Luscy, MD
Nephrology · Baton Rouge, LANPI 1255338521
Payments from drug & device makers
Across 265 payments — averaging $4064.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$608K
- GSK$249K
- Otsuka Pharmaceutical Co., Ltd.$154K
- Novartis$50K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$12K
- Fresenius USA Marketing, Inc.$1K
- plus $2K from 22 others
Across 3 payments — averaging $2706.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Co., Ltd.$8K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 16 | $607,848 |
| GSK | 46 | $248,835 |
| Otsuka Pharmaceutical Co., Ltd. | 27 | $154,244 |
| Novartis | 8 | $50,129 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $12,331 |
| Fresenius USA Marketing, Inc. | 61 | $1,172 |
| AstraZeneca | 35 | $788 |
| Medtronic | 18 | $412 |
| Sanofi | 10 | $306 |
| Amgen(2 entities) | 8 | $141 |
| Bayer | 1 | $119 |
| Bard Peripheral Vascular, Inc. | 3 | $107 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Amicus Therapeutics, Inc. | 4 | $75 |
| Abiomed | 1 | $60 |
| ANI Pharmaceuticals, Inc. | 3 | $51 |
| Calliditas Therapeutics US Inc. | 2 | $47 |
| Akebia Therapeutics Inc | 2 | $41 |
| Mallinckrodt Hospital Products Inc. | 2 | $39 |
| Vifor Pharma, Inc. | 2 | $34 |
| OPKO Pharmaceuticals, LLC | 2 | $31 |
| Mozarc Medical US LLC | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $27 |
| W. L. Gore & Associates, Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Chiesi USA, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
How this compares
$1,077,044 in reported general payments places this provider in the 95th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Baton Rouge
- Michael RoppoloBaton Rouge$447K
- Jones SamuelBaton Rouge$207K
- Amin KamyarBaton Rouge$88K
- Damodar KumbalaBaton Rouge$16K
- Robert LandryBaton Rouge$13K
- Raynold CoronaBaton Rouge$12K
- Kiran PadigalaBaton Rouge$6K
- Sreedhara AllaShreveport$1.2M
- Marwan KaskasShreveport$968K
- Juan Carlos VelezNew Orleans$801K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.